Evidence map›Paper›PMID 36339111›Full record

ReviewAnnals of medicine and surgery (2012)2022

Investigating thyroid dysfunction in the context of COVID-19 infection.

Aashna Mehta, Wireko Andrew Awuah, Rohan Yarlagadda, Jacob Kalmanovich, Helen Huang, Mrinmoy Kundu, Esther Patience Nansubuga, Leilani Lopes, Bikona Ghosh, Mohammad Mehedi Hasan

Open access · diamondAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Annals of medicine and surgery (2012), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.0field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 10 institutions in 7 countries.

Aashna MehtaUniversity of Debrecen-Faculty of Medicine, Debrecen, 4032, Hungary.
Wireko Andrew AwuahSumy State University, Sumy, Ukraine.
Rohan YarlagaddaRowan University School of Osteopathic Medicine, Stratford, NJ, USA.
Jacob KalmanovichDrexel University, College of Medicine, Philadelphia, PA, USA.
Helen HuangRoyal College of Surgeons in Ireland, University of Medicine and Health Science, Dublin, Ireland.
Mrinmoy KunduInstitute of Medical Sciences and SUM Hospital, Bhubaneswar, India.
Esther Patience NansubugaLeeds Medical School, University of Leeds, UK.
Leilani LopesWestern University of Health Sciences, College of Osteopathic Medicine of the Pacific-Northwest, Lebanon, OR, USA.
Bikona GhoshDhaka Medical College, Dhaka, Bangladesh.
Mohammad Mehedi HasanDepartment of Biochemistry and Molecular Biology, Faculty of Life Science, Mawlana Bhashani Science and Technology University, Tangail, Bangladesh.
Dhaka Medical College and Hospital · BDDrexel University · USInstitute of Medical Sciences and Sum Hospital · INMawlana Bhashani Science and Technology University · BDRowan University · USRoyal College of Surgeons in Ireland · IESumy State University · UAUniversity of Debrecen · HUUniversity of Leeds · GBWestern University of Health Sciences · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

COVID-19 is a contagious viral infection caused by severe acute respiratory syndrome coronavirus 2 (Sars-CoV-2). One of the key features of COVID-19 infection is inflammation. There is increasing evidence pointing to an association between cytokine storm and autoimmunity. One autoimmune disease of interest in connection to COVID-19 is hyperthyroidism. COVID-19 has been shown to decrease TSH levels and induce thyrotoxicosis, destructive thyroiditis, and de novo Graves' disease. It has also been suggested that the immune response against SARS-CoV-2 antigens following vaccination can cross-react through a mechanism called molecular mimicry which can elicit autoimmune reactivity, potentially leading to potential thyroid disease post vaccine. However, if the COVID-19 vaccine is linked to reduced COVID-19 related serious disease, it could potentially play a protective role against post COVID-19 hyperthyroidism (de novo disease and exacerbations). Further studies investigating the complex interplay between COVID-19 or COVID-19 vaccine and thyroid dysfunction can help provide substantial evidence and potential therapeutic targets that can alter prognosis and improve COVID-19 related outcomes in individuals with or without preexisting thyroid disease.

Identifiers

PMID36339111
PMCPMC9621589
OpenAlexW4307910049

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.